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Valorisation in its original sense means the creation of economic value. In biomedical 
research, valorisation aims to assess the contribution of scientific knowledge to indus-
trial activities and its application as potential products or services with societal benefit. 
This chapter is meant to position the scientific results from the preceding chapters in 
the context of social utilisation and to generate potential health care returns in appre-
ciation of public investments.  
 
Social relevance 
Getting the diagnosis of ‘cancer’ is a significant and dramatic incident for patients and 
their relatives. Prostate cancer (PCa) frequently shows an indolent clinical course with a 
2.5-3% lifetime risk of dying from progressive disease [1]. However, risk stratification 
remains a major clinical question. Since clinicopathologic criteria are insufficient to 
efficiently distinguish between indolent and aggressive tumors, patients experience 
uncertainty about the risk of disease progression, which means an additional burden to 
them. Knowledge about the molecular profiles of an individual tumor and its potential 
to progress could provide clinicians with valuable information about the clinical course 
and support treatment recommendations. Proper counseling and involvement in the-
rapy planning, especially of patients that could be considered for conservative mana-
gement, positively affects patient’s satisfaction after treatment [2]. Reducing over-
treatment of patients with insignificant disease on the one hand would decrease co-
morbidity as a consequence of the PCa treatment, such as a surgical procedure, with 
benefit for the quality of life and reduction of health care costs. The accurate selection 
of patients that need aggressive treatment on the other hand would improve prognosis 
by avoding a delay until initiation of a potentially effective treatment.  
 
Scientific and clinical relevance 
PCa is the most prevalent non-cutaneous malignancy accounting for 15% of the cancers 
diagnosed in men [3]. Depending on risk estimation, different treatment options are 
possible. During the decision-making process towards radical treatment versus conser-
vative management, clinicians use various prediction tools to determine patients that 
are at increased risk for disease progression. Those tools are based on clinicopathologic 
variables. However, PCa is a genomically complex disease. The molecular mechanisms 
and implications for clinical outcome of distinct genomic aberrations are yet poorly 
understood. Identification of the molecular profiles that promote aggressive tumor 
biology is therefore essential to support the prediction of progressive disease, and to 
recommend aggressive treatment to patients that will most likely benefit from it. 
In the studies compiled in this doctoral thesis, novel targets have been identified that 
provide insights into the molecular mechanisms of TMPRSS2:ERG fusion-positive PCa. 
Defining tumors by their individual genetic constitution, rather than histopathological 
patterns could lead to more accurate risk stratification.  
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Detection of the TMPRSS2:ERG gene fusion has currently no prognostic or therapeutic 
implications in routine clinical management. Determination of the gene fusion status 
could direct the selection of patients for clinical trials that are most likely to benefit 
from a molecularly targeted therapy reducing the number of required patients to ran-
domize and potentially increasing the chance of success of drug effectiveness testing 
(targeted design). This could further create an economically valuable strategy to control 
public investments into scientific research.   
 
We suggest that the TGF-β-ALK1 receptor-mediated signaling pathway in TMPRSS2:ERG 
positive tumors could be a promising candidate for future evaluation as therapy target 
in PCa. However, targeted therapy approaches are vulnerable to intrinsic resistance due 
to redundancy in signaling pathways in cancer cells [4]. Since ERG-mediated signaling 
deployed a second route, the FZD4-WNT signaling pathway, inhibition of both pathways 
could be considered as a combined concept to inhibit tumor activity. The identification 
of the two molecular determinants of epithelial-to-mesenchymal transition (EMT) in 
TMPRSS2:ERG positive tumors is therefore promising basis for future therapeutic ap-
proaches.  
 
Recognition of therapy resistance is important to avoid disease progression. Functional 
characterization of biological processes involved in therapy resistance could identify 
novel targets to improve clinical management. INSM1 was identified as promising regu-
lator of a neuroendocrine (NE) phenotype in PCa cells. The power of INSM1 lies in its 
specific overexpression in NE tumors. Since prostate cancers with NE characteristics are 
less likely to respond to hormonal agents, detection of INSM1 overexpression could be 
valuable in counseling patients towards a chemotherapeutic treatment or enrolment in 
a clinical trial [5]. 
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